SYBX - Spark Newswire

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

Today, 4:15 AM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

1 minute read

FDA
News

Synlogic-Sponsored Study Titled ‘Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers’ Posted To ClinicalTrials.Gov

By Benzinga Newsdesk

Today, 4:15 AM

https://clinicaltrials.gov/ct2/show/NCT04984525

SYBX

1 minute read

Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy

By Vandana Singh

Today, 4:15 AM

Synlogic Inc (NASDAQ:SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC:RHHBY) for the discovery of Synthetic Biotic medicine…

RHHBF

1 minute read

Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease

By Benzinga Newsdesk

Today, 4:15 AM

Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for

RHHBY

2 minute read

FDA
News

Synlogic Says Presents Additional Preclincal Data On Therapeutic Candidates SYNB1934 For Phenylketonuria And SYNB8802 For Enteric Hyperoxaluria At Synthetic Biology: Engineering, Evolution & Design Conference

By Benzinga Newsdesk

Today, 4:15 AM

Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic

SYBX

1 minute read

FDA
News

Synlogic Shares Quiet; Traders Circulate Co’s Poster Presentations Titled ‘Development of a Synthetic Biotic’ And ‘Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic’

By Benzinga Newsdesk

Today, 4:15 AM

https://investor.synlogictx.com/index.php/static-files/5597a995-f485-431e-b9a0-2541a78c6614 https://investor.synlogictx.com/index.php/static-files/67b4fe9d-d797-421d-b44b-4ed8fcd44b5f

SYBX

14 minute read

Uncategorized

Earnings Scheduled For May 13, 2021

By Benzinga Insights

Today, 4:15 AM

Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.

AACG

6 minute read

Uncategorized

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

By Shanthi Rexaline

Today, 4:15 AM

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.

ABCL

1 minute read

Uncategorized

3 Penny Stocks That Wall Street Wants You To Buy Now

By Mark Putrino

Today, 4:15 AM

Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt. Most penny stocks aren't followed by the Wall Street brokerage firms. It's not worth their time. The brokerage firms wouldn't recommend that their clients invest in them.

ABEO